Invention Grant
![Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders](/docs/US/2014-05-20/US08729127B2/abs.jpg.600x600.jpg)
- Patent Title: Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
-
Application No.: US13024681Application Date: 2011-02-10
-
Publication No.: US08729127B2Publication Date: 2014-05-20
- Inventor: Michael Graeber , Janusz Czernielewski
- Applicant: Michael Graeber , Janusz Czernielewski
- Applicant Address: FR Biot
- Assignee: Galderma Research & Development
- Current Assignee: Galderma Research & Development
- Current Assignee Address: FR Biot
- Agency: Dentons US LLP
- Priority: FR0203070 20020312
- Main IPC: A01N37/10
- IPC: A01N37/10 ; A61K31/19 ; A01N37/00 ; A61K31/185 ; A01N31/04 ; A61K31/07 ; A61K8/02 ; A61K9/00 ; A61K31/203 ; A61K47/48
![Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders](/abs-image/US/2014/05/20/US08729127B2/abs.jpg.150x150.jpg)
Abstract:
Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions.
Public/Granted literature
Information query
